Lorglumide: Difference between revisions

| StdInChI = 1S/C22H32Cl2N2O4/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28)

| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}

| StdInChIKey = IEKOTSCYBBDIJC-UHFFFAOYSA-N

}}

'''Lorglumide''' ('''CR-1409''') is a drug which inhibits gastrointestinal motility and reduces gastric secretions, acting as a [[cholecystokinin antagonist]],<ref>Makovec F, Bani M, Cereda R, Chisté R, Pacini MA, Revel L, Rovati LA, Rovati LC, Setnikar I. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. ~~''Arzneimittelforschung''.~~ ~~1987~~ ~~Nov;~~37(11~~):1265-8.~~ ~~PMID~~ 3440035</ref> with fairly high selectivity for the [[Cholecystokinin A receptor|CCKA]] subtype.<ref>González-Puga C, García-Navarro A, Escames G, León J, López-Cantarero M, Ros E, Acuña-Castroviejo D. Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin. ''Journal of Pineal Research~~''.~~ ~~2005~~ ~~Oct;~~39(3~~):243-50.~~ ~~{{DOI~~|10.1111/j.1600-079X.2005.00239.x}} ~~PMID~~ ~~16150104~~</ref> It has been suggested as a potential treatment for a variety of gastrointestinal problems including [[stomach ulcer]]s, [[irritable bowel syndrome]], [[dyspepsia]], [[constipation]] and [[pancreatitis]], as well as some forms of [[cancer]], but animal and human testing has produced inconsistent results and no clear therapeutic role has been established, although it is widely used in scientific research.<ref>de Tullio P, Delarge J, Pirotte B. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists). ''Current Medicinal Chemistry~~''.~~ ~~1999~~ ~~Jun;~~6(6~~):433-55~~. ~~PMID~~ 10213792</ref><ref>de Tullio P, Delarge J, Pirotte B. Therapeutic and chemical developments of cholecystokinin receptor ligands. ''Expert Opinion on Investigational Drugs~~''.~~ 2000 ~~Jan;~~9(1):129~~-46.~~ ~~PMID~~ ~~11060666~~</ref><ref>Herranz R. Cholecystokinin antagonists: pharmacological and therapeutic potential. ~~''Medical~~ Research Reviews~~''.~~ ~~2003~~ ~~Sep;~~23(5~~):559-605.~~ ~~PMID~~ 12789687</ref><ref>Berna MJ, Tapia JA, Sancho V, Jensen RT. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. ''Current Opinion in Pharmacology~~''.~~ ~~2007~~ ~~Dec;~~7(6~~):583-92.~~ ~~PMID~~ 17997137</ref>

'''Lorglumide''' ('''CR-1409''') is a drug which inhibits gastrointestinal motility and reduces gastric secretions, acting as a [[cholecystokinin antagonist]],<ref>{{cite journal | vauthors = Makovec F, Bani M, Cereda R, Chisté R, Pacini MA, Revel L, Rovati LA, Rovati LC, Setnikar I | display-authors = 6 | title = Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists | journal = Arzneimittel-Forschung | volume = 37 | issue = 11 | pages = 1265–8 | date = November 1987 | pmid = 3440035 }}</ref> with fairly high selectivity for the [[Cholecystokinin A receptor|CCKA]] subtype.<ref>{{cite journal | vauthors = González-Puga C, García-Navarro A, Escames G, León J, López-Cantarero M, Ros E, Acuña-Castroviejo D | title = Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin | journal = Journal of Pineal Research | volume = 39 | issue = 3 | pages = 243–50 | date = October 2005 | pmid = 16150104 | doi = 10.1111/j.1600-079X.2005.00239.x | s2cid = 20187767 }}</ref> It has been suggested as a potential treatment for a variety of gastrointestinal problems including [[stomach ulcer]]s, [[irritable bowel syndrome]], [[dyspepsia]], [[constipation]] and [[pancreatitis]], as well as some forms of [[cancer]], but animal and human testing has produced inconsistent results and no clear therapeutic role has been established, although it is widely used in scientific research.<ref>{{cite journal | vauthors = de Tullio P, Delarge J, Pirotte B | title = Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists) | journal = Current Medicinal Chemistry | volume = 6 | issue = 6 | pages = 433–55 | date = June 1999 | doi = 10.2174/0929867306666220330183253 | pmid = 10213792 | s2cid = 6031554 }}</ref><ref>{{cite journal | vauthors = de Tullio P, Delarge J, Pirotte B | title = Therapeutic and chemical developments of cholecystokinin receptor ligands | journal = Expert Opinion on Investigational Drugs | volume = 9 | issue = 1 | pages = 129–46 | date = January 2000 | pmid = 11060666 | doi = 10.1517/13543784.9.1.129 | s2cid = 39985897 }}</ref><ref>{{cite journal | vauthors = Herranz R | title = Cholecystokinin antagonists: pharmacological and therapeutic potential | journal = Medicinal Research Reviews | volume = 23 | issue = 5 | pages = 559–605 | date = September 2003 | pmid = 12789687 | doi = 10.1002/med.10042 | s2cid = 45758560 }}</ref><ref>{{cite journal | vauthors = Berna MJ, Tapia JA, Sancho V, Jensen RT | title = Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential | journal = Current Opinion in Pharmacology | volume = 7 | issue = 6 | pages = 583–92 | date = December 2007 | pmid = 17997137 | pmc = 2186776 | doi = 10.1016/j.coph.2007.09.011 }}</ref>

== References ==

[[Category:Cholecystokinin antagonists]]

[[Category:~~Organochlorides~~]]

[[Category:Chloroarenes]]

[[Category:Benzamides]]